Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 69

Similar articles for PubMed (Select 19763273)

1.

The cat and mouse of HIV-1 antibody escape.

Mascola JR.

PLoS Pathog. 2009 Sep;5(9):e1000592. doi: 10.1371/journal.ppat.1000592. Epub 2009 Sep 18. No abstract available.

2.

Virulence and pathogenesis of HIV-1 infection: an evolutionary perspective.

Fraser C, Lythgoe K, Leventhal GE, Shirreff G, Hollingsworth TD, Alizon S, Bonhoeffer S.

Science. 2014 Mar 21;343(6177):1243727. doi: 10.1126/science.1243727. Review.

PMID:
24653038
3.

Antibody selection and amino acid reversions.

da Silva J.

Evolution. 2012 Oct;66(10):3079-87. doi: 10.1111/j.1558-5646.2012.01686.x. Epub 2012 May 21.

PMID:
23025599
4.

HIV superinfection in women may boost immune response.

Rose S.

Expert Rev Anti Infect Ther. 2012 May;10(5):525. doi: 10.1586/eri.12.44. No abstract available.

PMID:
22702314
5.

Virus dynamics and evolution: bridging scales and disciplines.

Poss M.

Viruses. 2011 Aug;3(8):1432-8. doi: 10.3390/v3081432. Epub 2011 Aug 16. No abstract available.

6.

HIV vaccine development--improving on natural immunity.

Johnston MI, Fauci AS.

N Engl J Med. 2011 Sep 8;365(10):873-5. doi: 10.1056/NEJMp1107621. No abstract available.

7.

Effect of multiple infection of cells on the evolutionary dynamics of HIV in vivo: implications for host adaptation mechanisms.

Wodarz D, Levy DN.

Exp Biol Med (Maywood). 2011 Aug;236(8):926-37. doi: 10.1258/ebm.2011.011062. Epub 2011 Jul 18. Review.

PMID:
21768164
8.

An introduction to a novel population genetic approach for HIV characterization.

Perez-Sweeney B, DeSalle R, Ho JL.

Infect Genet Evol. 2010 Dec;10(8):1155-64. doi: 10.1016/j.meegid.2010.07.010. Epub 2010 Jul 14.

PMID:
20637314
9.

Challenges of antibody-mediated protection against HIV-1.

Lewis GK.

Expert Rev Vaccines. 2010 Jul;9(7):683-7. doi: 10.1586/erv.10.70. No abstract available.

10.

Few and far between: how HIV may be evading antibody avidity.

Klein JS, Bjorkman PJ.

PLoS Pathog. 2010 May 27;6(5):e1000908. doi: 10.1371/journal.ppat.1000908. No abstract available.

11.

HIV-1 autoreactive antibodies: are they good or bad for HIV-1 prevention?

Haynes BF, Nicely NI, Alam SM.

Nat Struct Mol Biol. 2010 May;17(5):543-5. doi: 10.1038/nsmb0510-543. No abstract available.

PMID:
20442740
12.

Emergence of monoclonal antibody b12-resistant human immunodeficiency virus type 1 variants during natural infection in the absence of humoral or cellular immune pressure.

Bunnik EM, van Gils MJ, Lobbrecht MS, Pisas L, Nanlohy NM, van Baarle D, van Nuenen AC, Hessell AJ, Schuitemaker H.

J Gen Virol. 2010 May;91(Pt 5):1354-64. doi: 10.1099/vir.0.017319-0. Epub 2010 Jan 6.

PMID:
20053822
13.

The implications of patterns in HIV diversity for neutralizing antibody induction and susceptibility.

Korber B, Gnanakaran S.

Curr Opin HIV AIDS. 2009 Sep;4(5):408-17. doi: 10.1097/COH.0b013e32832f129e. Review.

PMID:
20048705
14.

Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies.

Dieltjens T, Heyndrickx L, Willems B, Gray E, Van Nieuwenhove L, Grupping K, Vanham G, Janssens W.

Retrovirology. 2009 Dec 14;6:113. doi: 10.1186/1742-4690-6-113.

15.

Escape from autologous humoral immunity of HIV-1 is not associated with a decrease in replicative capacity.

Bunnik EM, Lobbrecht MS, van Nuenen AC, Schuitemaker H.

Virology. 2010 Feb 5;397(1):224-30. doi: 10.1016/j.virol.2009.11.009. Epub 2009 Nov 27.

16.

Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection.

Moore PL, Ranchobe N, Lambson BE, Gray ES, Cave E, Abrahams MR, Bandawe G, Mlisana K, Abdool Karim SS, Williamson C, Morris L; CAPRISA 002 Study; NIAID Center for HIV/AIDS Vaccine Immunology (CHAVI).

PLoS Pathog. 2009 Sep;5(9):e1000598. doi: 10.1371/journal.ppat.1000598. Epub 2009 Sep 18.

17.

Changing sensitivity to broadly neutralizing antibodies b12, 2G12, 2F5, and 4E10 of primary subtype B human immunodeficiency virus type 1 variants in the natural course of infection.

Bunnik EM, van Gils MJ, Lobbrecht MS, Pisas L, van Nuenen AC, Schuitemaker H.

Virology. 2009 Aug 1;390(2):348-55. doi: 10.1016/j.virol.2009.05.028. Epub 2009 Jun 17.

18.

In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth.

Shen X, Parks RJ, Montefiori DC, Kirchherr JL, Keele BF, Decker JM, Blattner WA, Gao F, Weinhold KJ, Hicks CB, Greenberg ML, Hahn BH, Shaw GM, Haynes BF, Tomaras GD.

J Virol. 2009 Apr;83(8):3617-25. doi: 10.1128/JVI.02631-08. Epub 2009 Feb 4.

19.

Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers.

Mahalanabis M, Jayaraman P, Miura T, Pereyra F, Chester EM, Richardson B, Walker B, Haigwood NL.

J Virol. 2009 Jan;83(2):662-72. doi: 10.1128/JVI.01328-08. Epub 2008 Nov 5.

20.

Systematic analysis of host immunological pressure on the envelope gene of human immunodeficiency virus type 1 by an immunobioinformatics approach.

Liang B, Luo M, Ball TB, Yao X, Van Domselaar G, Cuff WR, Cheang M, Jones SJ, Plummer FA.

Curr HIV Res. 2008 Jun;6(4):370-9.

PMID:
18691035
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk